LivaNova (NASDAQ:LIVN) was downgraded by BidaskClub from a “buy” rating to a “hold” rating in a research report issued on Thursday.
Several other equities analysts have also recently issued reports on LIVN. Canaccord Genuity restated a “hold” rating and set a $71.00 price objective on shares of LivaNova in a research note on Wednesday, September 20th. ValuEngine upgraded LivaNova from a “hold” rating to a “buy” rating in a research note on Thursday, November 2nd. Needham & Company LLC raised their price objective on LivaNova from $83.00 to $89.00 and gave the stock a “buy” rating in a research note on Friday, November 3rd. Jefferies Group raised their target price on LivaNova from $80.00 to $91.00 and gave the company a “buy” rating in a research note on Friday, November 3rd. Finally, Piper Jaffray Companies reiterated a “buy” rating and issued a $85.00 target price on shares of LivaNova in a research note on Friday, November 3rd. One analyst has rated the stock with a sell rating, five have assigned a hold rating and four have assigned a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $79.71.
Shares of LivaNova (LIVN) traded up $1.89 on Thursday, reaching $83.81. The company had a trading volume of 468,907 shares, compared to its average volume of 375,594. LivaNova has a 52-week low of $45.67 and a 52-week high of $88.56. The company has a market capitalization of $3,950.00 and a PE ratio of 22.35. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.03 and a quick ratio of 1.42.
LivaNova (NASDAQ:LIVN) last announced its quarterly earnings data on Thursday, November 2nd. The company reported $0.93 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.76 by $0.17. LivaNova had a return on equity of 9.33% and a net margin of 4.63%. The firm had revenue of $309.70 million for the quarter, compared to analysts’ expectations of $301.22 million. During the same period last year, the business posted $0.78 earnings per share. The firm’s revenue for the quarter was up 4.9% on a year-over-year basis. sell-side analysts predict that LivaNova will post 3.18 EPS for the current year.
In other LivaNova news, Director Hugh M. Morrison sold 1,830 shares of the firm’s stock in a transaction on Wednesday, November 29th. The stock was sold at an average price of $88.00, for a total value of $161,040.00. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Daniel Jeffrey Moore sold 1,000 shares of the firm’s stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $82.15, for a total value of $82,150.00. The disclosure for this sale can be found here. Insiders sold 6,830 shares of company stock worth $576,920 over the last quarter. 0.28% of the stock is currently owned by company insiders.
Hedge funds have recently bought and sold shares of the business. Redmile Group LLC acquired a new position in shares of LivaNova during the second quarter valued at $12,978,000. Koch Industries Inc. acquired a new position in shares of LivaNova during the second quarter valued at $1,384,000. State Street Corp increased its holdings in shares of LivaNova by 74.8% during the second quarter. State Street Corp now owns 1,835,428 shares of the company’s stock valued at $112,345,000 after purchasing an additional 785,268 shares during the period. Bessemer Group Inc. increased its holdings in shares of LivaNova by 625.0% during the third quarter. Bessemer Group Inc. now owns 26,100 shares of the company’s stock valued at $1,829,000 after purchasing an additional 22,500 shares during the period. Finally, Vanguard Group Inc. increased its holdings in shares of LivaNova by 13.6% during the second quarter. Vanguard Group Inc. now owns 883,058 shares of the company’s stock valued at $54,052,000 after purchasing an additional 105,702 shares during the period. Institutional investors own 86.00% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “LivaNova (LIVN) Stock Rating Lowered by BidaskClub” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The original version of this piece can be read at https://www.dispatchtribunal.com/2018/01/20/livanova-livn-stock-rating-lowered-by-bidaskclub.html.
LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company’s segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products.
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.